Medindia
Medindia LOGIN REGISTER
Advertisement

Commercial Insight: Osteoporosis - Market Players Maximize Revenue Growth Before the Next Challenging Phase Report now Available on ReportsandReports

Monday, June 7, 2010 General News
Advertisement
DALLAS, Texas, June 7, 2010 ReportsandReports Announce itWill Carry the Commercial Insight Osteoporosis Market Players MaximizeRevenue Growth Before the Next Challenging Phase Market Research Report (http://www.reportsandreports.com/Report/24113/) in its Store.
Advertisement

Browse the complete Report on:http://www.reportsandreports.com/market-reports/commercial-insight-osteoporosis-market-players-maximize-revenu/

(Due to the length of these URLs, it may be necessary to copy and pastethe hyperlinks into your Internet browser's URL address field. Remove thespace if one exists.)
Advertisement

Globally, the osteoporosis market displayed a 3.5% compound annual growthrate (CAGR) between 2005-09, reaching $9.4 billion in 2009. However, thelaunch of generic alendronate in the majority of markets resulted in atemporary decline in sales during 2009. The market will stabilize during thenext 5 years due to generic incursion and then resume growth from 2015 as newdrugs are launched.

Highlights

The rest of world, outside of the seven major markets, achievedosteoporosis-specific sales of $2.4 billion in 2009 with an impressive CAGRof 8.7% from 2005. Brazil, Russia, India and China were the fastest growingnations, driving a combined 2005-09 CAGR of 17%.

The osteoporosis market offers multiple opportunities for current andfuture market players. In addition to increasing awareness, diagnosis andtreatment, there is the need to develop new drugs that promote bone building.However, the increase in cost pressure resulting from generic penetrationposes a major barrier to entry.

Leading market players continue to pursue their direct-to-consumeradvertising campaigns, sponsoring events to raise awareness of the disorderand of respective treatments. Innovative strategies to increase brand loyaltyand confidence, such as risk-sharing schemes, have also been implemented byNovartis and Sanofi-Aventis.

Browse all Healthcare Market Research Reports (http://www.reportsandreports.com/market-research/healthcare/ )

Browse all Datamonitor Market Research Reports (http://www.reportsandreports.com/Publishers/datamonitor/ )

Related Reports

Osteoporosis Market Forecast http://www.reportsandreports.com/Report/8193/

Retail Banking Technology Spending Through 2014: Business FunctionSegmentation (Interactive Model) http://www.reportsandreports.com/Report/7225/

Retail Banking Technology Spending Through 2014: Source Segmentation(Interactive Model) http://www.reportsandreports.com/Report/7226/

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depthmarket research studies of over 5000 micro markets, and 25 industry specificwebsites. Our client list boasts almost all well-known publishers of suchreports across the globe. We as a third-party reseller of market researchreports employ a number of marketing tools, such as press releases,email-marketing and effective search-engine optimization techniques to driverevenues for our clients. We also provide 24/7 online and offline supportservice to our customers.Scope - Analysis of global osteoporosis prescriptions from 2005-09, split by geographical region (including emerging markets), drug class, and brand. - Discussion of key commercial opportunities and threats in the US, Japan, and five major European markets. - In depth profiles of 13 key osteoporosis brands and pipeline agents with SWOT analyses and country-specific sales forecasts to 2019. - Detailed analysis of key developer trends, strategies and portfolios including a case study of Novartis's Aclasta (zoledronic acid).

SOURCE Markets and Markets
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close